Eye diseases: Latest News, Top Stories & Analysis

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the European Commission has granted Advanced Therapy Medicinal Product (ATMP) classifications for its gene therapies OCU410 and OCU410ST. This regulatory milestone …

Business / Research

Ocugen Advances in Revolutionary Gene Therapy for Age-Related Macular Degeneration

April 21, 2024April 20, 2024 - by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of a groundbreaking treatment for geographic atrophy (GA), an advanced form of dry age-related macular …